PD-1/PD-L1

Overview

The PD-1/PD-L1 pathway is a critical immune checkpoint mechanism that plays a significant role in regulating the immune response, particularly in the context of cancer. Programmed cell death protein 1 (PD-1) is an inhibitory receptor expressed on activated T-lymphocytes, while CD274 molecule (PD-L1) is its ligand, predominantly found on tumor cells and antigen-presenting cells. The interaction between PD-1 and PD-L1 inhibits T-cell activation and proliferation, allowing tumors to evade immune surveillance. This pathway has become a focal point in cancer immunotherapy, with immune checkpoint inhibitors targeting PD-1 and PD-L1 demonstrating improved survival rates in various malignancies.

Recent Publications Summary

Recent studies have continued to examine PD-1/PD-L1 as a therapeutic target across cancer and other disease settings, with several reports focusing on ways to predict, modulate, or enhance checkpoint blockade. In non-small cell lung cancer, one study developed a multi-task masked autoencoder with GAN-based augmentation to predict PD-L1 expression directly from chest CT images, reporting improved performance over conventional supervised pretraining and single-task MAE approaches 42020694Apr. A complementary pathology resource introduced a multi-stain, multi-centric NSCLC digital pathology dataset with annotated PD-L1-positive tumor cell detection, supporting computational biomarker development for the tumor immune microenvironment 42009323Apr. Another NSCLC study examined age-associated targetable genomic alterations and PD-L1 expression in pulmonary ground-glass opacities, aiming to define how these features vary with age 42068110May.

Several publications explored strategies to improve the efficacy of PD-1/PD-L1 blockade by combining it with other interventions or by altering PD-L1 biology. In colorectal cancer mouse models, a Faecalibacterium prausnitzii enzyme, fpPRPS, was reported to reprogram PD-L1 trafficking, reduce suppression of T-cell responses, and sensitize tumors to immunotherapy; fpPRPS also synergized with anti-PD-1 treatment to promote CD8+ T-cell responses and tumor control 41998161Apr. metformin was shown to suppress PD-L1 expression through an SLC5A11-dependent AMPK-IRF1 axis, and combining metformin with anti-PD1 therapy produced synergistic antitumor effects in syngeneic lung and pancreatic cancer models 41690450Feb. In hepatocellular carcinoma, a bispecific antibody targeting GPC3 and PD-L1 was designed to enable tumor-directed PD-1/PD-L1 blockade, showing selective immune checkpoint inhibition in GPC3-high tumor cells and preferential activity in GPC3/PD-L1 double-positive tumors 41951084Apr. In ALK-rearranged NSCLC, gilteritinib was investigated as a means to overcome resistance to second-generation TKIs by inhibiting PD-L1 and CD8 co-expression, with in vitro, single-cell, and xenograft experiments used to assess antitumor effects 42059267Apr.

Other recent work highlighted the broader clinical and biological context of PD-1/PD-L1 targeting. A review of advanced biliary tract cancer noted that immune checkpoint inhibitors targeting PD-1 or PD-L1 have shown clinically meaningful activity, particularly when combined with cytotoxic chemotherapy, and are being incorporated into first-line treatment strategies 42026958Apr. In bladder cancer, limited efficacy of PD-1/PD-L1 immunotherapy was discussed in the context of adenosinergic immunosuppression, with CD39 and CD73 expression correlating with an immunosuppressive tumor microenvironment characterized by reduced CD8+ T-cell infiltration and increased regulatory T cells 42018002Apr. In T-cell acute lymphoblastic leukemia, a CCR4+ FOXP3+ regulatory T-cell subpopulation in the bone marrow was found to express immune checkpoints including PD-1 and TIGIT, suggesting a targetable immune context for anti-CCR4 therapy 41671457Feb. Outside oncology, investigators also explored PD-1 as a cellular target in HIV by engineering CAR-T cells against PD-1+ T cells, demonstrating persistence in humanized mice and providing proof-of-concept for depleting specific T-cell subpopulations to reduce the HIV reservoir 42030390Apr.

What Changes, What Holds

1. Computational and pathology tools now make PD-L1 more measurable, not more central
METHOD These studies do not alter the checkpoint biology in the Overview; they change how PD-L1 status can be inferred and annotated in NSCLC. The practical implication is better biomarker development from imaging and digital pathology, with the main uncertainty being whether these tools generalize beyond the datasets used. 42020694Apr42009323Apr

2. PD-1/PD-L1 blockade may be more effective when PD-L1 trafficking or expression is therapeutically reprogrammed
NEW DIRECTION fpPRPS and metformin both point to a broader use of the pathway than the Overview states: not just direct blockade, but upstream manipulation of PD-L1 biology to improve response. That leaves the baseline intact while adding a combination-therapy strategy, though both findings remain preclinical and need clinical validation. 41998161Apr41690450Feb

3. PD-1/PD-L1 targeting is expanding beyond a standalone cancer checkpoint into a context-dependent component of combination and non-oncology strategies
NEW DIRECTION The review in biliary tract cancer reinforces the established immunotherapy role, but the bladder, T-ALL, and HIV reports extend the entity into immunosuppressive microenvironments, regulatory T-cell biology, and reservoir-directed cellular engineering. None of this overturns the cancer checkpoint model; it broadens where PD-1/PD-L1 is being considered and what kinds of interventions may exploit it. 42026958Apr42018002Apr41671457Feb42030390Apr

Overview update candidates: combination strategies that modulate PD-L1 biology to enhance blockade; broader non-oncology and immune-cell engineering uses of PD-1 as a target.